Continuing Appropriations and Extensions Act, 2027
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill, the AGOA Extension Act, extends duty-free treatment for imports from eligible countries in sub-Saharan Africa (SSA) under the African Growth and Opportunity Act (AGOA) through December 31, 2028, and extends through December 31, 2031, customs user fees. It also includes a retroactive provision allowing refunds of duties paid on eligible SSA imports made after September 30, 2025, but before the bill's enactment, provided a request is filed with U.S. Customs and Border Protection within 180 days. The bill aims to support economic growth in SSA countries.
Key provisions
- Extends duty-free treatment for AGOA beneficiaries through December 31, 2028.
- Extends duty-free treatment for certain apparel articles from SSA countries through December 31, 2028.
- Extends the third-country fabric provision for apparel articles through December 31, 2028.
- Extends customs user fees through December 31, 2031.
- Provides for retroactive duty refunds for eligible SSA imports made after September 30, 2025.
- Specifies the timeframe for filing duty refund requests (within 180 days of enactment).
- Sets a timeframe for Customs and Border Protection to process and pay duty refunds (within 90 days).
- Defines ‘covered article’ as a beneficiary SSA country as of the date of enactment.
Who is affected
- Sub-Saharan African countries
- U.S. importers
- U.S. Customs and Border Protection
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
2 on record
Primary sponsor
Cosponsor
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours